Suppr超能文献

脑出血后重启或停用抗栓药物随机试验(RESTART):一项随机对照试验的研究方案

The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial.

作者信息

Al-Shahi Salman Rustam, Dennis Martin S, Murray Gordon D, Innes Karen, Drever Jonathan, Dinsmore Lynn, Williams Carol, White Philip M, Whiteley William N, Sandercock Peter A G, Sudlow Cathie L M, Newby David E, Sprigg Nikola, Werring David J

机构信息

Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, UK.

Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.

出版信息

Trials. 2018 Mar 5;19(1):162. doi: 10.1186/s13063-018-2542-6.

Abstract

BACKGROUND

For adults surviving stroke due to spontaneous (non-traumatic) intracerebral haemorrhage (ICH) who had taken an antithrombotic (i.e. anticoagulant or antiplatelet) drug for the prevention of vaso-occlusive disease before the ICH, it is unclear whether starting antiplatelet drugs results in an increase in the risk of recurrent ICH or a beneficial net reduction of all serious vascular events compared to avoiding antiplatelet drugs.

METHODS/DESIGN: The REstart or STop Antithrombotics Randomised Trial (RESTART) is an investigator-led, randomised, open, assessor-blind, parallel-group, randomised trial comparing starting versus avoiding antiplatelet drugs for adults surviving antithrombotic-associated ICH at 122 hospital sites in the United Kingdom. RESTART uses a central, web-based randomisation system using a minimisation algorithm, with 1:1 treatment allocation to which central research staff are masked. Central follow-up includes annual postal or telephone questionnaires to participants and their general (family) practitioners, with local provision of information about adverse events and outcome events. The primary outcome is recurrent symptomatic ICH. The secondary outcomes are: symptomatic haemorrhagic events; symptomatic vaso-occlusive events; symptomatic stroke of uncertain type; other fatal events; modified Rankin Scale score; adherence to antiplatelet drug(s). The magnetic resonance imaging (MRI) sub-study involves the conduct of brain MRI according to a standardised imaging protocol before randomisation to investigate heterogeneity of treatment effect according to the presence of brain microbleeds. Recruitment began on 22 May 2013. The target sample size is at least 720 participants in the main trial (at least 550 in the MRI sub-study).

DISCUSSION

Final results of RESTART will be analysed and disseminated in 2019.

TRIAL REGISTRATION

ISRCTN71907627 ( www.isrctn.com/ISRCTN71907627 ). Prospectively registered on 25 April 2013.

摘要

背景

对于因自发性(非创伤性)脑出血(ICH)而幸存的成年人,他们在脑出血前曾服用抗血栓药物(即抗凝剂或抗血小板药物)以预防血管闭塞性疾病,与避免使用抗血小板药物相比,开始使用抗血小板药物是否会增加复发性脑出血的风险,或是否能使所有严重血管事件的净风险有益降低,目前尚不清楚。

方法/设计:重启或停用抗血栓药物随机试验(RESTART)是一项由研究者主导的随机、开放、评估者盲法、平行组随机试验,在英国122个医院站点比较因抗血栓相关脑出血而幸存的成年人开始使用与避免使用抗血小板药物的情况。RESTART使用基于网络的中央随机化系统,采用最小化算法,按1:1分配治疗,中央研究人员对分配情况保密。中央随访包括每年向参与者及其全科(家庭)医生邮寄或电话问卷调查,并在当地提供不良事件和结局事件的信息。主要结局是复发性有症状脑出血。次要结局包括:有症状出血事件;有症状血管闭塞事件;不确定类型的有症状中风;其他致命事件;改良Rankin量表评分;抗血小板药物依从性。磁共振成像(MRI)子研究包括在随机分组前按照标准化成像方案进行脑部MRI检查,以根据脑微出血的存在情况研究治疗效果的异质性。招募工作于2013年5月22日开始。主要试验的目标样本量至少为720名参与者(MRI子研究至少550名)。

讨论

RESTART的最终结果将于2019年进行分析和发布。

试验注册

ISRCTN71907627(www.isrctn.com/ISRCTN71907627)。于2013年4月25日进行前瞻性注册。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47b7/5838871/3d48712c8f7e/13063_2018_2542_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验